Xcout IntelBioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
Subscribe to see BioXcel Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BioXcel Therapeutics, Inc. at a glance
BioXcel Therapeutics, Inc. is a biopharmaceuticals company headquartered in New Haven, United States. It is publicly listed (BTAI) with a market capitalisation of $24.8M. Xcout tracks 21 named people at BioXcel Therapeutics, Inc., including Richard I. Steinhart (Senior Vice President & Chief Financial Officer).
BioXcel Therapeutics, Inc. leadership
- Richard I. SteinhartSenior Vice President & Chief Financial Officer
- Frank D. YoccaExecutive Vice President & Chief Scientific Officer
- Javier RodriguezSenior Vice President, Chief Legal Officer & Corporate Secretary
- Mark PavaoActing Chief Commercial Officer
- Peter Mueller, Ph.D.Chairman of the Board
- Vimal D. MehtaFounder, Chief Executive Officer, President, & Director
15 more named people on record for BioXcel Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
BioXcel Therapeutics, Inc. competitors
A few of BioXcel Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
Kebotix is a technology company founded in 2017 and headquartered in Cambridge, Massachusetts. The firm is dedicated to tackling major scientific challenges by leveraging advanced digital tools and artificial intelligence to revolutionize research and development in materials science.
Biohaven is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across key therapeutic areas. Headquartered with operations in New Haven, Connecticut, the company advances innovative neuroscience and specialty therapeutics.
Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III development for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.
Nexalis Health, Inc. (operating as Nexalis Therapeutics) is a clinical-stage biopharmaceutical company that develops oral and inhaled therapies for pain management and mental health conditions. Its pipeline includes three drug candidates addressing treatment-resistant depression, breakthrough cancer pain, and panic disorder.
Cerevel Therapeutics was a U.S. biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, and Alzheimer’s disease. Its therapies were intended to serve patients with serious central nervous system conditions and the healthcare providers treating them.
Get BioXcel Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BioXcel Therapeutics, Inc. in Xcout Intel
- 21 named people with titles, LinkedIn and board committees
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access